Table 1. Baseline patient characteristics.

UPN	Sex	Age	Duration of AHD (months)	AHD type	MDS subtype (FAB)	MDS subtype (WHO)	IPSS-R	Transformation to AML	Cause of death	Cytogenetic abnormalities	Follow up time (years)	Sampling moments(n)
1	F	51	7	Anaemia	RAEB	RAEB-1	High	No	NA	del5q, t(X;16)	11.2	19
2	M	62	7	Anaemia	RARS	RARS	Very low	No	TBC	NN	5.0	5
3	M	56	40	Anaemia	RARS	RARS	Very low	No	Prostate cancer	NN	7.7	6
4	M	66	43	Granulocytopenia	RAEB	RAEB-1	Low	No	NA	NN	8.1	9
5	M	64	66	Thrombocytopenia	RA	RCMD	Int	Yes	AML	+8	7.0	6
6	M	58	6	Anaemia	RARS	RCMD	Low	No	MDS/pneumonia	+21	5.3	5
7	M	67	81	Pancytopenia	RAEB	RAEB-1	Int	Yes	AML	NN	3.7	7
8	F	67	40	Anaemia, Granulocytopenia	RAEB	RAEB-1	Int	No	NA	del5q, t(1;10)	11.3	13
9	F	73	69	Anaemia	RA	RA	Low	No	Heart failure	del5q, del9q	6.6	13
10	F	57	70	Thrombocytosis	RA	RCMD	Int	No	NA	del5q, del13q	9.3	31
11	M	67	0	NA	RA	RCMD	Int	Yes	AML	NN	2.4	6

AHD, antecedent haematological disease; AML, acute myeloid leukaemia; F, female; FAB, French–American–British classification system; Int, intermediate; IPSS-R, Revised International Prognostic Scoring System; M, male; NA, not applicable; NN, normal karyotype. RA, refractory anaemia; RAEB-1, refractory anaemia with excess blasts-1; RARS, refractory anaemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; TBC, tuberculosis; UPN, unique patient number; WHO, World Health Organization classification system.